Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.

Identifieur interne : 000067 ( PubMed/Curation ); précédent : 000066; suivant : 000068

COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.

Auteurs : Thomas P. Lodise [États-Unis] ; Michael J. Rybak [États-Unis]

Source :

RBID : pubmed:32267556

Abstract

We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.1-3 However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.

DOI: 10.1002/phar.2396
PubMed: 32267556

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:32267556

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.</title>
<author>
<name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name>
<affiliation wicri:level="1">
<nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Albany College of Pharmacy and Health Sciences, Albany, NY</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name>
<affiliation wicri:level="1">
<nlm:affiliation>Wayne State University, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wayne State University, Detroit, MI</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32267556</idno>
<idno type="pmid">32267556</idno>
<idno type="doi">10.1002/phar.2396</idno>
<idno type="wicri:Area/PubMed/Corpus">000067</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000067</idno>
<idno type="wicri:Area/PubMed/Curation">000067</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000067</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.</title>
<author>
<name sortKey="Lodise, Thomas P" sort="Lodise, Thomas P" uniqKey="Lodise T" first="Thomas P" last="Lodise">Thomas P. Lodise</name>
<affiliation wicri:level="1">
<nlm:affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Albany College of Pharmacy and Health Sciences, Albany, NY</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rybak, Michael J" sort="Rybak, Michael J" uniqKey="Rybak M" first="Michael J" last="Rybak">Michael J. Rybak</name>
<affiliation wicri:level="1">
<nlm:affiliation>Wayne State University, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Wayne State University, Detroit, MI</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Pharmacotherapy</title>
<idno type="eISSN">1875-9114</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.
<sup>1-3</sup>
However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="Publisher" Owner="NLM">
<PMID Version="1">32267556</PMID>
<DateRevised>
<Year>2020</Year>
<Month>04</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1875-9114</ISSN>
<JournalIssue CitedMedium="Internet">
<PubDate>
<Year>2020</Year>
<Month>Apr</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Pharmacotherapy</Title>
<ISOAbbreviation>Pharmacotherapy</ISOAbbreviation>
</Journal>
<ArticleTitle>COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.2396</ELocationID>
<Abstract>
<AbstractText>We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.
<sup>1-3</sup>
However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.</AbstractText>
<CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lodise</LastName>
<ForeName>Thomas P</ForeName>
<Initials>TP</Initials>
<AffiliationInfo>
<Affiliation>Albany College of Pharmacy and Health Sciences, Albany, NY, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rybak</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Wayne State University, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>04</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Pharmacotherapy</MedlineTA>
<NlmUniqueID>8111305</NlmUniqueID>
<ISSNLinking>0277-0008</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32267556</ArticleId>
<ArticleId IdType="doi">10.1002/phar.2396</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000067 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32267556
   |texte=   COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:32267556" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021